PearX

Pear

Healthcare
Playbook

a podcast by Pear VC

Listen & subscribe

Substack
Apple Podcast
Spotify

We share stories from trailblazing entrepreneurs on how to build a healthcare business from 0 to 1.

Latest episodes

View all

More episodes

View all
View all

Biotech

Here are some of the things we’re interested in, but there are far more than what we’ve shared on this page. If you’re building something cool, we want to hear from you, regardless of whether it’s listed here or not.

Novel therapeutic discovery platforms

We are interested in novel therapeutic discovery platforms that leverage omics-based measurement technologies such as single-cell sequencing, spatial transcriptomics, and proteomics, or that rely on manipulation techniques with a high degree of plexity or parallelization. Especially when the resulting large data sets can be analyzed with powerful computational and ML-based approaches, these technologies hold the potential to unveil previously hidden insights into the cellular and molecular basis of disease.

Next-generation therapeutic modalities

Emerging therapeutic modalities, such as genomic medicines (including gene therapy, RNA therapeutics, and gene editing), cell therapies, targeted protein degraders, and antibody-drug conjugates, have enabled more precise and effective treatments for a range of diseases and have expanded the universe of druggable targets. We are interested in technologies that can dramatically improve the efficacy, safety, and reach of these modalities.

Precision medicine

The use of biomarkers for patient selection has significantly bolstered the likelihood of successful translation for drug programs in oncology and have enabled therapeutic product profiles with better efficacy and safety. We are excited about the broader integration of biomarker-guided drug development strategies, not only within oncology but also across diverse therapeutic areas.

Software platforms for biopharma

We anticipate software platforms will play an increasingly pivotal role across all parts of the drug development value chain, including drug discovery, clinical development, manufacturing, and sales and marketing.

Healthcare

Here are some of the things we’re interested in, but there are far more than what we’ve shared on this page. If you’re building something impactful, we want to hear from you, regardless of whether it’s listed here or not.

Healthcare AI

The US healthcare system has reached a crucial juncture, presenting immense opportunities to leverage new data standards and the abundance of healthcare data. This, in turn, enables the development of AI solutions that enhance and automate both non-clinical and clinical workflows, optimizing efficiency and improving patient outcomes.

Tech-enabled care delivery

Envision a world where every patient, irrespective of their condition or background, can effortlessly receive timely, personalized, and specialized care from the comfort of their own home.

Healthcare tech stack

Despite advancements, many software systems in healthcare still rely on outdated methods like fax machines and hand-written forms. Providers should prioritize clinical care rather than being burdened with disjointed records, scheduling, note-taking, or compliance tasks attributed to their systems.

Healthcare fintech

Exciting new avenues to translate new modalities of fintech in healthcare. These include value-based contracting, revenue cycle management and back office automation, which aim to drive accessible care by reducing costs and inefficiencies in outdated payment systems. These modalities hold promise for a more streamlined and affordable healthcare experience, while rewarding providers for quality care.

Pharma R&D and commercial

By leveraging software, we can streamline the drug discovery, development, and distribution process, ensuring that groundbreaking medicines reach patients more efficiently. This entails facilitating pre-clinical and commercial collaboration, expediting scientific discovery and clinical trials, and ensuring regulatory compliance. With these advancements, we can accelerate the delivery of innovative treatments to those in need.

Meet the current co-hosts

View all

Andrew Parambath

Learn more

Rachel Gleyzer

Learn more

Anson Zhou

Learn more

Joseph Marsilio

Learn more

Stay in the loop

Subscribe